Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies
Toxicologic Pathology · 2024
DOI: 10.1177/01926233241248654 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, 2024. Verfasst von Kevin S McDorman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Charles River Laboratories, Inc., Frederick, Maryland, USA. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Toxicology, Peer Review, Pathology. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
In December 2021, the United States Food and Drug Administration (FDA) issued the final guidance for industry titled Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers . The stated purpose of the FDA guidance is to provide information to sponsors, applicants, and nonclinical laboratory personnel regarding the management and conduct of histopathology peer review as part of nonclinical toxicology studies conducted in compliance with good laboratory practice (GLP) regulations. On behalf of and in collaboration with global societies of toxicologic pathology and the Society of Quality Assurance, the Scientific and Regulatory Policy Committee (SRPC) of the Society of Toxicologic Pathology (STP) initiated a review of this FDA guidance. The STP has previously published multiple papers related to the scientific conduct of a pathology peer review of nonclinical toxicology studies and appropriate documentation practices. The objectives of this review are to provide an in-depth analysis and summary interpretation of the FDA recommendations and share considerations for the conduct of pathology peer review in nonclinical toxicology studies that claim compliance to GLP regulations. In general, this working group is in agreement with the recommendations from the FDA guidance that has added clear expectations for pathology peer review preparation, conduct, and documentation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Charles River Laboratories, Inc., Frederick, Maryland, USA.
- Magenta Therapeutics, Cambridge, Massachusetts, USA.
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
- Biogen, Cambridge, Massachusetts, USA.
- Mersana Therapeutics Inc, Cambridge, Massachusetts, USA.
- U.S. Food & Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Kevin S McDorman, Bindu M Bennet, Karyn Colman, James D Fikes, Barbara Munch, Annette Romeike, Kenneth A Schafer, Frédéric Schorsch, Heath C Thomas, Sean Troth, John L Vahle, Frank J Geoly
Zitieren
APA
McDorman, K. S., Bennet, B. M., Colman, K., Fikes, J. D., Keirstead, N. D., Lanning Retired, L., Munch, B., Romeike, A., Schafer, K. A., Schorsch, F., Thibodeau, M. S., Thomas, H. C., Troth, S., Vahle, J. L., & Geoly, F. J. (2024). Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies. Toxicologic Pathology. https://doi.org/10.1177/01926233241248654
Vancouver
McDorman KS, Bennet BM, Colman K, Fikes JD, Keirstead ND, Lanning Retired L, et al. Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies. Toxicologic Pathology. 2024. doi:10.1177/01926233241248654
BibTeX
@article{McDorman2024,
author = {McDorman, Kevin S and Bennet, Bindu M and Colman, Karyn and Fikes, James D and Keirstead, Natalie D and Lanning Retired, Lynda and Munch, Barbara and Romeike, Annette and Schafer, Kenneth A and Schorsch, Frédéric and Thibodeau, Michael S and Thomas, Heath C and Troth, Sean and Vahle, John L and Geoly, Frank J},
title = {Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies},
journal = {Toxicologic Pathology},
year = {2024},
doi = {10.1177/01926233241248654}
}
EUVIMED